NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Expedition Therapeutics

Expedition Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://expeditiontx.com/

Last Round

Series A

Oct 9, 2025

Est. Valuation

$650M

Total Funding Raised

$165M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverytherapeutic candidatesbiotechclinical trialssmall-molecule inhibitorDPP1 inhibitorrespiratory diseaseCOPD treatmentdrug developmentbiopharmapreclinical developmentlicensing agreementmilestone paymentspharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Expedition Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Expedition Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Expedition Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 9, 2025

Key People

Founding team and executive leadership

Yi Larson

President And CEO

Executive Team

Expedition Therapeutics Investors

Notable investors and investment history

Expedition Therapeutics investors
InvestorRounds
Balyasny Asset Management L.P.Series A
Lake Bleu CapitalSeries A
ForbionSeries A
Logos CapitalSeries A
Novo HoldingsSeries A
BVF Partners L.P.Series A
Adage Capital ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 25, 2026

    Grew 56% QoQ, from 9 to 14 employees.

  • Apr 24, 2026

    Grew 86% QoQ, from 7 to 13 employees.

Expedition Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Expedition Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Expedition Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range14
Year Founded2024
Last FundingOct 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.